Abstract：
OBJECTIVE: Investigation of diagnostic and prognostic relevance of BRCA1 immunohistochemistry (IHC) in endometrial carcinoma.
METHODS: Ninty four specimens of endometrial carcinomas were evaluated. Full sections stained with hematoxylin & eosin were revaluated for assessment of tumor type, grade, myometrial, & lympho-vascular invasion (LVI). Tissue microarray blocks were constructed using the pencil tip method and immunostained with Anti-BRCA1 antibody. BRCA1 was correlated with clinicopathological parameters as well as disease free survival and overall survival.
RESULTS: There was a statistically significant difference (P=0.001) between serous and endometroid carcinomas regarding BRCA1 expression where most cases of serous carcinoma showed negative expression. No statistically significant difference was found between BRCA1 positive and negative cases regarding disease free survival (DFS) or overall survival. Serous histotype, high grade, advanced stage, and omental deposits were the parameters significantly associated with decreased DFS.
CONCLUSIONS: Results of this study can support inclusion of BRCA1 IHC in a panel to differentiate both endometroid and serous carcinomas. The current study found no prognostic relevance for BRCA1 in terms of overall survival and disease-free survival.
METHODS: Ninty four specimens of endometrial carcinomas were evaluated. Full sections stained with hematoxylin & eosin were revaluated for assessment of tumor type, grade, myometrial, & lympho-vascular invasion (LVI). Tissue microarray blocks were constructed using the pencil tip method and immunostained with Anti-BRCA1 antibody. BRCA1 was correlated with clinicopathological parameters as well as disease free survival and overall survival.
RESULTS: There was a statistically significant difference (P=0.001) between serous and endometroid carcinomas regarding BRCA1 expression where most cases of serous carcinoma showed negative expression. No statistically significant difference was found between BRCA1 positive and negative cases regarding disease free survival (DFS) or overall survival. Serous histotype, high grade, advanced stage, and omental deposits were the parameters significantly associated with decreased DFS.
CONCLUSIONS: Results of this study can support inclusion of BRCA1 IHC in a panel to differentiate both endometroid and serous carcinomas. The current study found no prognostic relevance for BRCA1 in terms of overall survival and disease-free survival.
摘要：
目的：研究子宫内膜癌BRCA1免疫组织化学（IHC）的诊断和预后相关性。
方法：对94例子宫内膜癌标本进行评估。重新评估用苏木精和伊红染色的完整切片以评估肿瘤类型，grade,子宫肌层,&淋巴血管浸润（LVI）。使用笔尖方法构建组织微阵列块并用抗BRCA1抗体免疫染色。BRCA1与临床病理参数以及无病生存率和总生存率相关。
结果：在BRCA1表达方面，浆液性癌和金属内膜癌之间存在统计学上的显着差异（P=0.001），其中大多数浆液性癌病例显示阴性表达。在BRCA1阳性和阴性病例之间，无疾病生存期（DFS）或总生存期无统计学意义。浆液性组织型,高品位,高级阶段,和网膜沉积是与DFS降低显着相关的参数。
结论：这项研究的结果可以支持将BRCA1IHC纳入一组以区分金属内膜癌和浆液性癌。目前的研究发现BRCA1在总生存期和无病生存期方面没有预后相关性。
方法：对94例子宫内膜癌标本进行评估。重新评估用苏木精和伊红染色的完整切片以评估肿瘤类型，grade,子宫肌层,&淋巴血管浸润（LVI）。使用笔尖方法构建组织微阵列块并用抗BRCA1抗体免疫染色。BRCA1与临床病理参数以及无病生存率和总生存率相关。
结果：在BRCA1表达方面，浆液性癌和金属内膜癌之间存在统计学上的显着差异（P=0.001），其中大多数浆液性癌病例显示阴性表达。在BRCA1阳性和阴性病例之间，无疾病生存期（DFS）或总生存期无统计学意义。浆液性组织型,高品位,高级阶段,和网膜沉积是与DFS降低显着相关的参数。
结论：这项研究的结果可以支持将BRCA1IHC纳入一组以区分金属内膜癌和浆液性癌。目前的研究发现BRCA1在总生存期和无病生存期方面没有预后相关性。
